Novel compounds
DC
First Claim
Patent Images
1. A compound of formula (I):
- ##STR92## or a tautomeric form thereof and/or pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein;
A1 represents a substituted or unsubstituted, single ring aromatic heterocyclyl group having 4 to 7 ring atoms and comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen, the substituents for the heterocyclyl group being up to 4 substituents selected from the group consisting of;
C1-12 -alkyl, C1-12 -alkoxy, aryl and halogen or any two substituents on adjcent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted;
R1 represents a hydrogen atom, a C1-12 -alkyl group, a C1-6 alkylcarbonyl group, an aryl-C1-12 -alkyl group the aryl moiety being substituted or unsubstituted, or a substituted or unsubstituted aryl group;
any aryl group being phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C1-12 -alkyl, phenyl, C1-12 -alkoxy, halo-C1-12 -alkyl, hydroxy, amino, nitro, carboxy, C1-12 -alkylcarbonyloxy, or a C1-12 -alkylcarbonyl group;
Rhu 2 and R3 each represent hydrogen, or R2 and R3 together represent a bond;
A2 represents a benzene ring having three optional substituents which may be selected from halogen, substituted or unsubstituted alkyl or alkoxy;
substituents for the alkyl group being selected from the groups consisting of halogen, C1-12 -alkyl, phenyl, C1-12 -alkoxy, halo-C1-12 -alkyl, hydroxy, amino, nitro, carboxy, C1-12 -alkoxycarbonyl, C1-12 -alkoxycarbonyl-C1-12 -alkyl, C1-12 -alkylcarbonyloxy, or C1-12 -alkylcarbonyl; and
n represents an integer in the range of from 2 to 6.
4 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein:
A1 represents a substituted or unsubstituted aromatic heterocyclyl group;
R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;
R2 and R3 each represent hydrogen, or R2 and R3 together represent a bond;
A2 represents a benzene ring having in total up to five substituents; and
n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.
226 Citations
55 Claims
-
1. A compound of formula (I):
- ##STR92## or a tautomeric form thereof and/or pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein;
A1 represents a substituted or unsubstituted, single ring aromatic heterocyclyl group having 4 to 7 ring atoms and comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen, the substituents for the heterocyclyl group being up to 4 substituents selected from the group consisting of;
C1-12 -alkyl, C1-12 -alkoxy, aryl and halogen or any two substituents on adjcent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted;R1 represents a hydrogen atom, a C1-12 -alkyl group, a C1-6 alkylcarbonyl group, an aryl-C1-12 -alkyl group the aryl moiety being substituted or unsubstituted, or a substituted or unsubstituted aryl group; any aryl group being phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C1-12 -alkyl, phenyl, C1-12 -alkoxy, halo-C1-12 -alkyl, hydroxy, amino, nitro, carboxy, C1-12 -alkylcarbonyloxy, or a C1-12 -alkylcarbonyl group; Rhu 2 and R3 each represent hydrogen, or R2 and R3 together represent a bond; A2 represents a benzene ring having three optional substituents which may be selected from halogen, substituted or unsubstituted alkyl or alkoxy;
substituents for the alkyl group being selected from the groups consisting of halogen, C1-12 -alkyl, phenyl, C1-12 -alkoxy, halo-C1-12 -alkyl, hydroxy, amino, nitro, carboxy, C1-12 -alkoxycarbonyl, C1-12 -alkoxycarbonyl-C1-12 -alkyl, C1-12 -alkylcarbonyloxy, or C1-12 -alkylcarbonyl; andn represents an integer in the range of from 2 to 6. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)
- ##STR92## or a tautomeric form thereof and/or pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeSmithkline Beecham Corporation (Smithkline Beecham PLC)
-
Original AssigneeBeecham Group PLC (GlaxoSmithKline PLC)
-
InventorsHindley, Richard M.
-
Primary Examiner(s)Gerstl, Robert
-
Application NumberUS07/457,272Time in Patent Office454 DaysField of Search548/182, 548/181, 548/161, 546/280, 544/332, 514/369, 514/367, 514/342, 514/275US Class Current514/275CPC Class CodesA61P 3/06 AntihyperlipidemicsA61P 3/08 for glucose homeostasis pan...A61P 3/10 for hyperglycaemia, e.g. an...A61P 9/12 AntihypertensivesC07D 277/20 having two or three double ...C07D 277/22 with only hydrogen atoms, h...C07D 277/42 Amino or imino radicals sub...C07D 277/82 Nitrogen atomsC07D 417/12 linked by a chain containin...
